Pre-transplant sTIM-3 levels may have a predictive impact on transplant outcome in acute leukemia patients

YEGİN Z. A., Can F., Aydin Kaynar L., GÖKÇEN S., Eren Sadioglu R., ÖZKURT Z. N., ...Daha Fazla

HEMATOLOGY, cilt.25, sa.1, ss.125-133, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1080/16078454.2020.1738097
  • Dergi Adı: HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.125-133
  • Anahtar Kelimeler: TIM-3, acute myeloid leukemia, acute lymphoblastic leukemia, allogeneic hematopoietic stem cell transplantation, graft versus host disease, viral hemorrhagic cystitis, prognosis, cytogenetics, VERSUS-HOST-DISEASE, CONSENSUS DEVELOPMENT PROJECT, ACUTE MYELOID-LEUKEMIA, PLASMA BIOMARKERS, NEUTROPENIC PATIENTS, EUROPEAN CONFERENCE, CLINICAL-TRIALS, STEM-CELLS, T-CELLS, TIM-3
  • Gazi Üniversitesi Adresli: Evet

Özet

Objectives:T-cell immunoglobulin and mucin domain-containing protein-3 (TIM-3) is considered as a negative regulator of T-cell driven immune response. This study is planned to investigate the prognostic role of pre-transplant soluble TIM-3 (sTIM-3) levels in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients.Methods:Pre-transplant serum sTIM-3 levels were measured in 177 allo-HSCT recipients [median age: 36(16-66) years; male/female: 111/66].Results:Pre-transplant sTIM-3 levels were significantly higher in acute myeloid leukemia (AML) patients compared to acute lymphoblastic leukemia (ALL) patients (p = 0.01). Pre-transplant sTIM-3 levels were significantly lower in patients with abnormal cytogenetics (p = 0.017). Pre-transplant sTIM-3 levels were significantly higher in patients who developed viral hemorrhagic cystitis (p = 0.034). A positive correlation was demonstrated between sTIM-3 levels and acute graft versus host disease (GvHD) grade (p = 0.013;r = 0.299). Overall survival (OS) was not statistically different between low- and high-TIM-3 groups (%35.2 vs %20.4;p > 0.05). Primary diagnosis (p = 0.042), sinusoidal obstruction syndrome (p < 0.001), acute GvHD (p = 0.001), chronic GvHD (p = 0.009) and post-transplant relapse (p = 0.003) represented significant impact on OS.Discussion:Increased sTIM-3 levels in AML patients seem to be compatible with the previous reports. The inhibitor role of TIM-3 in cellular immune response may be a possible explanation for the association of sTIM-3 with viral infections and GvHD. However, the main challenge remains to be the ambiguous association of pre-transplant sTIM-3 levels and post-transplant complications, as allo-HSCT recipients are expected to represent donor genetic features in the post-transplant setting.Conclusion:Further studies are warranted to clarify the particular role of sTIM-3 in the allo-HSCT setting.